138 related articles for article (PubMed ID: 3109461)
1. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
James CA; Mant TG; Rogers HJ
Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of orally administered mesna.
Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
[TBL] [Abstract][Full Text] [Related]
3. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
Shaw IC; Weeks MS
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
[TBL] [Abstract][Full Text] [Related]
4. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
Ormstad K; Orrenius S; Låstbom T; Uehara N; Pohl J; Stekar J; Brock N
Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
[TBL] [Abstract][Full Text] [Related]
7. The fate of [14C]-mesna in the rat.
Shaw IC; Graham MI; Jones MS
Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
[TBL] [Abstract][Full Text] [Related]
8. Oral bioavailability of mesna tablets.
Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
[TBL] [Abstract][Full Text] [Related]
9. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
Reuther H; Kohl M; Wildenauer DB
Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
[TBL] [Abstract][Full Text] [Related]
10. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
Jones MS; Murrell RD; Shaw IC
Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
[TBL] [Abstract][Full Text] [Related]
11. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
Habs MR; Schmähl D
Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Brock N; Stekar J
Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
[TBL] [Abstract][Full Text] [Related]
13. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat.
Ormstad K; Uehara N
FEBS Lett; 1982 Dec; 150(2):354-8. PubMed ID: 6819161
[TBL] [Abstract][Full Text] [Related]
14. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
Leeuwenkamp OR; Neijt JP; van der Vijgh WJ; Pinedo HM
Eur J Cancer; 1991; 27(10):1243-7. PubMed ID: 1835593
[TBL] [Abstract][Full Text] [Related]
15. Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.
Al-Safi SA; Maddocks JL
Br J Clin Pharmacol; 1986 Mar; 21(3):267-70. PubMed ID: 2938613
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
Goren MP; Anthony LB; Hande KR; Johnson DH; Brade WP; Frazier MW; Bush DA; Li JT
J Clin Oncol; 1998 Feb; 16(2):616-21. PubMed ID: 9469350
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
el-Yazigi A; Yusuf A; al-Rawithi S
Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
[TBL] [Abstract][Full Text] [Related]
19. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection.
James CA; Rogers HJ
J Chromatogr; 1986 Oct; 382():394-8. PubMed ID: 3097045
[No Abstract] [Full Text] [Related]
20. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
Roth B; Cerny T; Brunner KW; Küpfer A
Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
